UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000033854
Receipt No. R000038572
Scientific Title A randomized, placebo-controlled, double-blind, parallel-group trial of the improvement in ocular function with continued lutein intake
Date of disclosure of the study information 2018/09/04
Last modified on 2019/05/13

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A randomized, placebo-controlled, double-blind, parallel-group trial of the improvement in ocular function with continued lutein intake
Acronym A randomized, placebo-controlled, double-blind, parallel-group trial of the improvement in ocular function with continued lutein intake
Scientific Title A randomized, placebo-controlled, double-blind, parallel-group trial of the improvement in ocular function with continued lutein intake
Scientific Title:Acronym A randomized, placebo-controlled, double-blind, parallel-group trial of the improvement in ocular function with continued lutein intake
Region
Japan

Condition
Condition Healthy subjects
Classification by specialty
Adult
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 The objective of this study is to evaluate the effect of the study food containing lutein on ocular function in healthy Japanese men and women aged 20 years or older and 69 years or younger who continue to consume the food for 16 weeks.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Macular pigment optical density
Key secondary outcomes Serum lutein concentration, contrast sensitivity

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Double blind -all involved are blinded
Control Placebo
Stratification YES
Dynamic allocation NO
Institution consideration Institution is not considered as adjustment factor.
Blocking NO
Concealment Central registration

Intervention
No. of arms 2
Purpose of intervention Prevention
Type of intervention
Food
Interventions/Control_1 16-week intake of the containing lutein food of 2 capsules a day
Interventions/Control_2 16-week intake of the placebo food of 2 capsules a day
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
69 years-old >=
Gender Male and Female
Key inclusion criteria 1)Healthy Japanese men and women aged 20 to 69 years at the time of informed consent
2)Persons with a BMI 25 kg of less than or equal to m2
3)Patients who have not undergone LASIK surgery (myopia correction surgery)
4)Patients with 0.7 or more corrected visual acuity in both eyes
5)Persons who can be contacted by personal computer or smartphone
6)Patients who can discontinue ophthalmic solutions during the study period.
7)A person who has received sufficient explanation on the purpose and content of the research, who has the ability to give consent, who voluntarily volunteers to participate in the research with a good understanding, and who has given written consent to participate in the research.
Key exclusion criteria 1)A person who is currently receiving any drug treatment or ambulatory treatment.
2)A person who is currently exercising or taking diet under the supervision of a physician.
3)Patients with a history of, present disease, or complication of liver disease or serious renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematologic, or metabolic disease.
4)Patients with chronic diseases (arrhythmias, hepatic disorders, renal disorders, cerebrovascular disorders, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or other chronic diseases) who are being treated or have a history
5)Patients who have undergone gastrointestinal surgery (appendicitis is acceptable)
6)Patients with eye diseases other than refractive error (hyperopia, myopia, astigmatism)
7)Persons with a history of drug or food allergy
8)People who wish to do so during pregnancy, lactation, or the duration of the study
9)Persons who have received blood donations or immunizations within the last 3 months or who plan to receive them during the study period.
10)Persons who routinely consume health foods, supplements, and pharmaceuticals that may affect ocular function.
11)Persons with psychiatric disorders (depression, etc.) or sleep disorders who are attending hospital or who have a history of psychiatric illness in the past
12)Alcoholics, addicts, or abusers with or without a history of treatment
13)Persons who work on a shift basis, such as those who work at night
14)Persons with extremely irregular lifestyle habits such as diet and sleep
15)Current smokers
16)Currently participating in other clinical trials or participating in other clinical trials within the last 3 months of the date of informed consent
17)Persons with difficulties in observing records on various questionnaires
18)Other persons who are judged by the investigator to be inappropriate for the study.
Target sample size 62

Research contact person
Name of lead principal investigator
1st name Kosehira
Middle name
Last name Marie
Organization Omnica Co.,Ltd
Division name Research and development Dept.
Zip code 112-0002
Address TN Koishikawa BLDG. 5F, 1-15-17 Koishikawa, Bunkyo-ku, Tokyo, JAPAN
TEL 03-5840-9815
Email kosehira@omnica.co.jp

Public contact
Name of contact person
1st name Daisuke
Middle name
Last name Ochitani
Organization HUMA R&D CORP
Division name Clinical Development Division
Zip code 108-0014
Address Oekkusu Bldg10F 5-31-19 Shiba Minato-ku Tokyo 108-0014 Japan
TEL 81-3-3431-1260
Homepage URL
Email ochitani@huma-rd.co.jp

Sponsor
Institute HUMA R&D CORP
Institute
Department

Funding Source
Organization Omnica Co.,Ltd
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization Japan

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Ethics Committees of Nihonbashi Egawa Clinic
Address 2F Kotobuki Build. 1-27-12 Yaesu Chuo-ku, Tokyo 103-0028 Japan
Tel 03-5204-0311
Email jim@medipharma.co.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2018 Year 09 Month 04 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled 62
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2018 Year 08 Month 10 Day
Date of IRB
2018 Year 08 Month 13 Day
Anticipated trial start date
2018 Year 09 Month 05 Day
Last follow-up date
2019 Year 01 Month 19 Day
Date of closure to data entry
2019 Year 01 Month 21 Day
Date trial data considered complete
2019 Year 02 Month 06 Day
Date analysis concluded
2019 Year 05 Month 31 Day

Other
Other related information

Management information
Registered date
2018 Year 08 Month 22 Day
Last modified on
2019 Year 05 Month 13 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038572

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.